This is the first study to compare the efficacy of faecal BAFF with faecal calprotectin and FOBT for discriminating IBS from IBD and assessment of intestinal inflammation in IBD after we identified BAFF as a novel biomarker in IBD16. This evidence concerns the gene TNFSF13B and irritable bowel syndrome.